Background: Previous studies have verified that Inscuteable Spindle Orientation Adaptor Protein (INSC) can regulate cell proliferation and differentiation in the developing nervous system. It also plays an important role in spindle orientation during mitosis and asymmetric division of fibroblasts and participates in the process of stratification of the squamous epithelium. The role and potential mechanism of INSC in the development of colonic adenocarcinoma (COAD) have not been fully understood. This study aimed at exploring the prognostic value of INSC in COAD and the correlation of its expression with immune infiltration.Methods: The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) project, Gene Expression Profiling Interactive Analysis (GEPIA), and Gene Expression Omnibus (GEO) database were used to analyze the expression of INSC in COAD. The INSC protein expression level was analyzed by immunohistochemistry staining and the Human Protein Atlas (HPA) database. The diagnostic and prognostic values of INSC in COAD patients were analyzed using receiver operating characteristic (ROC) and Kaplan–Meier (KM) survival curves. In order to understand whether INSC is an independent prognostic factor, we used univariable and multivariate Cox analyses to analyze INSC expression and several clinical characteristics with survival. We use STRING analysis to find INSC-related proteins and related biological events analyzed by Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. At last, GEPIA and the Tumor Immune Estimation Resource (TIMER) were employed to explore the relationship between INSC and immune infiltrates and its marker gene set.Results: INSC was lower expressed in COAD tissues than in normal colon tissues, which was correlated with tumor stage. Patients with lower expression of INSC had shorter overall survival (OS). Moreover, univariable Cox analysis demonstrated that high expression of INSC was an independent prognostic factor for COAD. ROC analysis showed INSC was an accurate marker for identifying tumors from normal colon tissue, and the AUC of the curve was 0.923. Significant GO term analysis by GSEA showed that genes correlated with INSC were found to be enriched in several immune-related pathways. Specifically, INSC expression showed significant negative correlations with infiltration levels of B cells, CD4+ T cells, macrophages, DCs, and their marker sets in COAD.Conclusion: INSC was provided with prognostic value in COAD and related to immune invasion.
Background: Ovarian cancer (OV) is the most prevalent and lethal gynecologic malignancy globally. Cisplatin remains the first-line chemotherapeutic regimen for OV; however, chemotherapy resistance poses a persistent clinical challenge in gynecologic oncology. Parthenolide, a naturally derived phytochemical, exhibits broad-spectrum antitumor activity. Recent studies suggest that parthenolide may reverse cisplatin-resistance in OV when used in combination therapy. This study aims to elucidate the molecular targets and mechanisms underlying parthenolide-mediated reversal of cisplatin-resistance by integrating network pharmacology and molecular docking approaches. Methods: Platinum-resistant and control OV gene expression datasets were retrieved from the gene expression omnibus database. Differentially expressed genes (DEGs) were identified using the limma R package. Cellular enrichment patterns in platinum-resistant and control samples were analyzed via single-sample Gene Set Enrichment Analysis (ssGSEA). Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify modules associated with differentially enriched cell types. A protein-protein interaction network of overlapping genes from DEGs and WGCNA-identified genes was constructed to pinpoint hub genes. Receiver operating characteristic (ROC) curves assessed the diagnostic utility of hub genes. Molecular docking and binding pocket analysis were performed to explore parthenolide-protein interactions. Results: A total of 3582 DEGs were identified between platinum-resistant and control samples, enriched in biological processes (e.g., cell junction assembly), cellular components (e.g., collagen-containing extracellular matrix), and molecular functions (e.g., signaling receptor activation). WGCNA revealed 331 genes correlated with differentially enriched cell types. Subsequent overlap analysis identified 266 immunity-related genes in platinum-resistant OV. Hub genes, including apolipoprotein E, demonstrated diagnostic value via ROC analysis. Molecular docking highlighted β2-microglobulin, brain-derived neurotrophic factor, cellular communication network factor 2, and activator protein-1 as parthenolide targets, with binding pocket analysis identifying critical interaction residues. Conclusions: This study identifies candidate genes linked to cisplatin-resistance and delineates molecular mechanisms by which parthenolide may counteract resistance, supporting its clinical application in OV therapy.